Mounjaro: Important Update for Our Patients at Haus of Ästhetik

Why We’re Sharing This With You

At Haus of Ästhetik, we believe our patients deserve clear, honest information about their treatments — especially when big changes are happening in the industry.

From 1 September 2025, Eli Lilly, the manufacturer of Mounjaro (tirzepatide), will increase UK private market prices by up to 170%. We want you to understand what’s changing, why it’s happening, and how we’re working to keep your care safe, regulated, and as affordable as possible.

 

What’s Changing?

• Private prescriptions will cost more – for example, the highest monthly dose will rise from around £122 to £330.
• NHS supply stays the same – if you are eligible under the NHS pathway, your prescription cost remains at the standard NHS charge, but availability is limited.
• Safety warnings are increasing – the MHRA and FDA are warning against fake or unlicensed versions sold online, which can be dangerous or ineffective.

Why This Is Happening

• Global price alignment – Eli Lilly says UK prices are being brought in line with other European markets.
• High worldwide demand – Mounjaro is in huge demand for both weight loss and type 2 diabetes, with supply still catching up.
• Manufacturing scale-up – New production sites are being built to improve availability, but these take time to come online.

Our Promise to You

At Haus of Ästhetik:

• We will only supply Mounjaro sourced from fully regulated UK pharmacies.
• We are committed to offering the most reasonable prices we can, even with the upcoming manufacturer increases.
• We will never compromise on patient safety to cut costs.
• Our team will personally discuss any changes to your treatment plan or pricing with you before September.

Staying Safe

Counterfeit and unregulated versions of Mounjaro are being sold through social media ads, unofficial websites, and even some “compounding” pharmacies abroad. These may contain incorrect doses or harmful substances.

To protect yourself:

• Always get your prescription from a qualified UK prescriber.
• Ensure your medicine is dispensed by a registered UK pharmacy.
• Avoid buying from social media adverts, “research use only” sites, or overseas sellers.

If you suspect a fake product or experience unexpected side effects, you can report it via the MHRA Yellow Card Scheme.

If Cost Becomes a Concern

We know this price increase will impact some patients. If you are paying privately:

• Speak to us early about your options.
• We can review other GLP-1 treatments that may be more affordable and still effective for your needs.
• We can discuss NHS eligibility if your circumstances fit the NICE criteria.

Looking Ahead

Over the next 6–12 months:

• Private prices will rise in September.
• NHS weight management access will expand gradually but remains selective.
• Supply should improve as new manufacturing sites open.
• Regulators will continue to target counterfeit and unlicensed products.

The Bottom Line

At Haus of Ästhetik, our focus is on safe, regulated, and transparent care. We will continue to work hard to keep Mounjaro accessible for our patients while protecting you from unsafe alternatives.

If you have questions about your current treatment or want to discuss your options before the September price change, please contact us directly.

#Mounjaro #Tirzepatide #WeightLoss #Type2Diabetes #NHS #UKHealth #GLP1 #PatientSafety #MHRA #ObesityCare #HausOfAsthetik

 

References

1. Reuters – Eli Lilly to raise UK list price of Mounjaro by 170%
2. The Guardian – UK Mounjaro price rise and NHS access
3. NICE – Tirzepatide for managing overweight and obesity (TA1026)
4. MHRA – Counterfeit medicine safety alerts
5. FDA – Unapproved GLP-1 products warning